Phase 1 CLTX-CAR T cell Study in Glioblastoma

Phase 1 CLTX-CAR T cell Study in Glioblastoma2021-01-11T03:54:00+00:00

  • Investigator Sponsored Study
  • First patient dosed in September 2020
  • Approx 18 patients
  • Recurrent/progressive glioblastoma
  • Assess safety
  • Determine the maximum tolerated dose schedule (MTD) and a recommended Phase 2 dosing plan (RP2D)
  • Estimate: six month progression free survival (PFS) rate; nine month overall survival (OS) rate: median overall survival (OS)
  • Principal Investigator – Prof Behnam Badie at COH
  • Currently screening patients – CAR-T Cells with a Chlorotoxin Tumor-Targeting Domain for Glioblastoma

*None of Chimeric’s product pipeline has received marketing authorization in any jurisdiction. Any use of Chimeric’s products is on an investigational basis or for use in approved clinical trials.

Prof Behnam Badie – Vice Chair and Professor, Department of Surgery; Chief, Division of Neurosurgery; Director, Brain Tumor Program